New research from the nonprofit Employee Benefit Research Institute signals — in time for open enrollment season on the exchange — the prediction didn’t come to pass. Between 2014 and 2022, institute researchers found that more people had access to benefits, as the share of eligible workers rose 5 percentage points.
“Widespread access [to the new antibody drug] will take time across many sectors of the pediatric population and won’t have as great an impact on volumes this immediate respiratory season,” the Children’s Hospital Association said in a statement.
